Similar articles for PMID: 21932937

Year	Number of Results
1998	1
1999	1
2004	1
2006	2
2007	6
2008	5
2009	5
2010	13
2011	29
2012	42
2013	48
2014	25
2015	26
2016	32
2017	27
2018	18
2019	13
2020	15
2021	13
2022	12
2023	4
2024	0

1

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T. Goldstein R, et al. Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20. Expert Rev Anticancer Ther. 2011. PMID: 21932937 Review.

2

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL. Thompson LA, et al. Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Ann Pharmacother. 2012. PMID: 22947595 Review.

3

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM. Chan HY, et al. Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Adv Ther. 2010. PMID: 20623346 Free article. Review.

4

Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.

[No authors listed] [No authors listed] Prescrire Int. 2012 Oct;21(131):234. Prescrire Int. 2012. PMID: 23185844 Review.

5

Medical treatment of neuroendocrine tumours.

Weber HC. Weber HC. Curr Opin Endocrinol Diabetes Obes. 2013 Feb;20(1):27-31. doi: 10.1097/MED.0b013e32835c034f. Curr Opin Endocrinol Diabetes Obes. 2013. PMID: 23221494 Review.

6

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.

Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, Gouysse G, Ferraro-Peyret C, Benslama N, Walter T, Scoazec JY, Roche C. Bollard J, et al. Neuroendocrinology. 2013;97(4):331-40. doi: 10.1159/000347063. Epub 2013 May 22. Neuroendocrinology. 2013. PMID: 23343749 Free article.

7

Everolimus for the treatment of pancreatic neuroendocrine tumors.

Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P. Feldmann G, et al. Expert Opin Pharmacother. 2012 Oct;13(14):2073-84. doi: 10.1517/14656566.2012.713348. Epub 2012 Aug 8. Expert Opin Pharmacother. 2012. PMID: 22873789 Review.

8

[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].

Lombard-Bohas C, Cariou B, Vergès B, Coriat R, N'guyen T, François E, Hammel P, Niccoli P, Hentic O. Lombard-Bohas C, et al. Bull Cancer. 2014 Feb;101(2):175-83. doi: 10.1684/bdc.2014.1887. Bull Cancer. 2014. PMID: 24557872 Review. French.

9

Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.

Wolin EM. Wolin EM. Chemotherapy. 2014;60(3):143-50. doi: 10.1159/000369780. Epub 2015 Mar 7. Chemotherapy. 2014. PMID: 25766415

10

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Yao JC, et al. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. N Engl J Med. 2011. PMID: 21306238 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

304 results

Results by year